Submission Details
| 510(k) Number | K203084 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 13, 2020 |
| Decision Date | August 31, 2021 |
| Days to Decision | 322 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K203084 is an FDA 510(k) clearance for the Ablamap Software, a Computer, Diagnostic, Programmable (Class II — Special Controls, product code DQK), submitted by Ablacon, Inc. (Denver, US). The FDA issued a Cleared decision on August 31, 2021, 322 days after receiving the submission on October 13, 2020. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.1425.
| 510(k) Number | K203084 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 13, 2020 |
| Decision Date | August 31, 2021 |
| Days to Decision | 322 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | DQK — Computer, Diagnostic, Programmable |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.1425 |